tax and financial advisers in connection with making a decision regarding the acquisition. Freeline Therapeutics Holdings NewsMORE Related Stocks ...

Freeline Therapeutics, a Phase 1/2 biotech developing gene therapies for rare diseases, announced terms for its IPO on Monday. The Stevenage, UK-based company plans to raise $125 million by ...